comparemela.com

Latest Breaking News On - Tibet rhodiola pharmaceutical holding - Page 1 : comparemela.com

Russia to cooperate with China on production of Sputnik V vaccine_GMW cn

2021-05-09 18:57   By: Xinhua   Photo taken on April 28, 2021 shows the COVID-19 vaccines Sputnik V in Moscow, Russia. [Photo/Xinhua] MOSCOW - The Russian Direct Investment Fund (RDIF) has signed deals with three Chinese biopharmaceutical companies for the production of over 260 million doses of its Sputnik V vaccine against the coronavirus in the past weeks, according to statements published on the website of the RDIF. The first contract was signed with China s Shenzhen Yuanxing Gene-tech Co., Ltd. on March 29 for the production of over 60 million doses of the Sputnik V jab that is scheduled to start this month. Another agreement was reached on April 1 with a subsidiary of a key leader in the pharmaceutical field, the Tibet Rhodiola Pharmaceutical Holding, namely TopRidge Pharma, for the production of over 100 million doses per year.

Russia to cooperate with China on production of Sputnik V vaccine - World News

2021-05-07 15:35:20 GMT2021-05-07 23:35:20(Beijing Time) Xinhua English   Photo taken on April 28, 2021 shows the COVID-19 vaccines "Sputnik V" in Moscow, Russia. (Xinhua/Evgeny Sinitsyn) MOSCOW, May 7 (Xinhua) The Russian Direct Investment Fund (RDIF) has signed deals with three Chinese biopharmaceutical companies for the production of over 260 million doses of its Sputnik V vaccine against the coronavirus in the past weeks, according to statements published on the website of the RDIF. The first contract was signed with China s Shenzhen Yuanxing Gene-tech Co., Ltd. on March 29 for the production of over 60 million doses of the Sputnik V jab that is scheduled to start this month.

Russia to cooperate with China on production of Sputnik V vaccine

Russia to cooperate with China on production of Sputnik V vaccine Xinhua 08 May 2021, 02:05 GMT+10 MOSCOW, May 7 (Xinhua) The Russian Direct Investment Fund (RDIF) has signed deals with three Chinese biopharmaceutical companies for the production of over 260 million doses of its Sputnik V vaccine against the coronavirus in the past weeks, according to statements published on the website of the RDIF. The first contract was signed with China s Shenzhen Yuanxing Gene-tech Co., Ltd. on March 29 for the production of over 60 million doses of the Sputnik V jab that is scheduled to start this month. Another agreement was reached on April 1 with a subsidiary of a key leader in the pharmaceutical field, the Tibet Rhodiola Pharmaceutical Holding, namely TopRidge Pharma, for the production of over 100 million doses per year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.